Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evolus, Inc.EOLS · Entity 5341 | Director | February 17, 2026 | February 19, 2026 |
| MELINTA THERAPEUTICS, INC. /NEW/MLNT · Entity 154249 | Director | June 11, 2019 | June 12, 2019 |
| Ocugen, Inc.HSGX · Entity 5550 | Director | June 15, 2018 | June 19, 2018 |
| STRATA Skin Sciences, Inc.SSKN · Entity 72980 | Director | November 22, 2019 | November 26, 2019 |
| Strongbridge Biopharma plcSBBP · Entity 131608 | Director | October 05, 2021 | October 06, 2021 |
| Telix Pharmaceuticals LtdTLX · Entity 4101 | Director | May 11, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evolus, Inc.
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 86,887 |
Reported balance
After 2026-02-17 transaction · row 1
1 source rowRow 1 · 2026-02-17 · Grant · Acquired 45,559 · Balance 86,887 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 17, 2026, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 17, 2026, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer.
MELINTA THERAPEUTICS, INC. /NEW/
Report date June 11, 2019 · Filed June 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Melinta Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 30,000 |
Reported balance
After 2019-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date.
Ocugen, Inc.
Report date June 15, 2018 · Filed June 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.97 · Expires 2028-06-14 | Direct | 25,000 |
Reported balance
After 2018-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-15 · Grant · Acquired 25,000 · Balance 25,000 F1: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018.
STRATA Skin Sciences, Inc.
Report date November 22, 2019 · Filed November 26, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| SSKN Common StockSEC Table I · non-derivative | Direct | 64,694 |
Reported balance
After 2019-11-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-11-22 · Grant · Acquired 18,293 · Balance 64,694 F1: Represents Restricted Stock Units issued to the recipient, in lieu of a portion of his Board compensation, on November 22, 2019 at the closing price of $2.46. The Restricted Stock Units will vest 100%, in equal quarterly installments, over a 12 month period. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units issued to the recipient, in lieu of a portion of his Board compensation, on November 22, 2019 at the closing price of $2.46. The Restricted Stock Units will vest 100%, in equal quarterly installments, over a 12 month period.
Strongbridge Biopharma plc
Report date October 05, 2021 · Filed October 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 1
1 source rowRow 1 · 2021-10-05 · Disposition to issuer · Disposed 78,058 · Balance 0 F1: Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election. |
Filing footnotes · ownership attribution and instrument terms
F1: Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election.
Telix Pharmaceuticals Ltd
Report date May 11, 2026 · Filed May 18, 2026
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EndoChoice Holdings, Inc.
Report date November 22, 2016 · Filed November 23, 2016
Section 16 reporting ended · disclosed 2016-11-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-11-22 transaction · row 1
1 source rowRow 1 · 2016-11-22 · Disposition to issuer · Disposed 125,445 · Balance 0 F1: From April 1, 2016 through and including November 14, 2016, the reporting person transferred directly held shares to his indirectly held joint living trust, which resulted in a decrease in direct shares held and an increase in indirect shares held. F2: Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer. |
| Common stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy David N. Gill & Diane P. Gill Joint Living Trust | 0 |
Reported balance
After 2016-11-22 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2016-11-22 · Disposition to issuer · Disposed 38,585 · Balance 0 F1: From April 1, 2016 through and including November 14, 2016, the reporting person transferred directly held shares to his indirectly held joint living trust, which resulted in a decrease in direct shares held and an increase in indirect shares held. F2: Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.31 · Expires 2026-03-29 | Direct | 0 |
Reported balance
After 2016-11-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-11-22 · Disposition to issuer · Disposed 32,230 · Balance 0 F3: This option was cancelled pursuant to the Merger in exchange for a cash payment representing the difference between the exercise price of the option and the merger consideration of $8.00 per share. F4: Issuer's outstanding stock options, if not yet vested, became fully vested pursuant to the terms and conditions of the Merger. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.01 · Expires 2025-08-14 | Direct | 0 |
Reported balance
After 2016-11-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-11-22 · Disposition to issuer · Disposed 53,825 · Balance 0 F4: Issuer's outstanding stock options, if not yet vested, became fully vested pursuant to the terms and conditions of the Merger. F5: This option was cancelled pursuant to the Merger. Since the exercise price of this option exceeded the merger consideration of $8.00 per common shares, no value was received by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: From April 1, 2016 through and including November 14, 2016, the reporting person transferred directly held shares to his indirectly held joint living trust, which resulted in a decrease in direct shares held and an increase in indirect shares held.
F2: Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer.
F3: This option was cancelled pursuant to the Merger in exchange for a cash payment representing the difference between the exercise price of the option and the merger consideration of $8.00 per share.
F4: Issuer's outstanding stock options, if not yet vested, became fully vested pursuant to the terms and conditions of the Merger.
F5: This option was cancelled pursuant to the Merger. Since the exercise price of this option exceeded the merger consideration of $8.00 per common shares, no value was received by the reporting person.
Y-mAbs Therapeutics, Inc.
Report date September 16, 2025 · Filed September 18, 2025
Section 16 reporting ended · disclosed 2025-09-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-09-16 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2025-09-16 · Disposition to issuer · Disposed 5,825 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, the Shares were tendered at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive $8.60 per Share, in cash, without interest, subject to any applicable withholding of taxes (the "Merger Consideration"). At the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL) (the "Effective Time"), each issued and outstanding Share was cancelled in exchange for the Merger Consideration. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-09-16 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2025-09-16 · Disposition to issuer · Disposed 25,080 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F3: Represents restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU. F4: At the Effective Time, pursuant to the Merger Agreement, each RSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the total number of Shares issuable in settlement of such RSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.16 · Expires 2028-04-24 | Direct | 0 |
Reported balance
After 2025-09-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-09-16 · Disposition to issuer · Disposed 24,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.45 · Expires 2029-06-12 | Direct | 0 |
Reported balance
After 2025-09-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-09-16 · Disposition to issuer · Disposed 16,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.67 · Expires 2030-06-23 | Direct | 0 |
Reported balance
After 2025-09-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-09-16 · Disposition to issuer · Disposed 11,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.53 · Expires 2031-06-10 | Direct | 0 |
Reported balance
After 2025-09-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-09-16 · Disposition to issuer · Disposed 11,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.64 · Expires 2032-07-15 | Direct | 0 |
Reported balance
After 2025-09-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-09-16 · Disposition to issuer · Disposed 16,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.13 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2025-09-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-09-16 · Disposition to issuer · Disposed 13,950 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.01 · Expires 2034-06-11 | Direct | 0 |
Reported balance
After 2025-09-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-09-16 · Disposition to issuer · Disposed 14,545 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.51 · Expires 2035-06-30 | Direct | 0 |
Reported balance
After 2025-09-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-09-16 · Disposition to issuer · Disposed 33,450 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").
F2: Pursuant to the terms of the Merger Agreement, the Shares were tendered at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive $8.60 per Share, in cash, without interest, subject to any applicable withholding of taxes (the "Merger Consideration"). At the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL) (the "Effective Time"), each issued and outstanding Share was cancelled in exchange for the Merger Consideration.
F3: Represents restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU.
F4: At the Effective Time, pursuant to the Merger Agreement, each RSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the total number of Shares issuable in settlement of such RSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration.
F5: At the Effective Time, pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 22, 2019 Filed Nov 26, 2019 16:33 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Common Stock | 18,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001051514-19-000128 · form4.xml · nonDerivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,694 F1 · security: Represents Restricted Stock Units issued to the recipient, in lieu of a portion of his Board compensation, on November 22, 2019 at the closing price of $2.46. The Restricted Stock Units will vest 100%, in equal quarterly installments, over a 12 month period. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 16:19 UTC | Strongbridge Biopharma plc SBBP · Entity 131608 | GrantOrdinary Shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-010059 · edgar.xml · nonDerivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Represents a grant of restricted stock units, which vest in full on September 3, 2020, provided that the Reporting Person continues to serve as a member of the board of directors of the Issuer through that date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 21:59 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock | 2,000 | $13.65 | $27,300.00 |
DisclosureSEC source: 0001570562-19-000103 · wf-form4_156056397196003.xml · nonDerivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:18 UTC | Y-mAbs Therapeutics, Inc. YMAB · Entity 75095 | GrantNon-Employee Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $21.45 | $0.00 |
DisclosureSEC source: 0001104659-19-035670 · a4.xml · derivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2029-06-12 F1 · security: Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. F2 · derivative.exercise_date: The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service on the board of directors of Y-mAbs Therapeutics, Inc., and are exercisable immediately upon vesting. Read SEC document |
| June 11, 2019 Filed Jun 12, 2019 13:37 UTC | MELINTA THERAPEUTICS, INC. /NEW/ MLNT · Entity 154249 | GrantMelinta Restricted Stock Units · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001461993-19-000031 · wf-form4_156036102095305.xml · derivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Melinta Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date. F1 · derivative.expiration_date: The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 20:18 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $16.19 | $0.00 |
DisclosureSEC source: 0001570562-19-000019 · wf-form4_154846548092960.xml · derivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2029-01-23 F1 · derivative.exercise_date: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of January 23, 2019, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| December 14, 2018 Filed Dec 17, 2018 21:51 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock | 3,000 | $12.77 | $38,300.10 |
DisclosureSEC source: 0001570562-18-000130 · wf-form4_154510147610889.xml · nonDerivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · price: The shares were purchased in multiple trades at prices ranging from $12.72 to $12.84. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 16:42 UTC | Ocugen, Inc. HSGX · Entity 5550 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0000899243-18-017191 · doc4.xml · derivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-06-14 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 16:53 UTC | MELINTA THERAPEUTICS, INC. /NEW/ MLNT · Entity 154249 | GrantStock Option (right to buy) · Derivative | 9,100 | $0.00 Strike: $7.45 | $0.00 |
DisclosureSEC source: 0000899243-18-016633 · doc4.xml · derivative · entry 2 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,100 Underlying: Common Stock · 9,100 shares Expires 2028-04-20 F1 · date: The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 16:53 UTC | MELINTA THERAPEUTICS, INC. /NEW/ MLNT · Entity 154249 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $7.45 | $0.00 |
DisclosureSEC source: 0000899243-18-016633 · doc4.xml · derivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-04-20 F1 · date: The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018. F2 · derivative.exercise_date: One-third of the shares underlying the stock option will vest and become exercisable on April 20, 2019. The remainder will vest and become exercisable in substantially equal monthly installments during the two year period commencing on April 20, 2019. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 18:18 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSTRATA Restricted Stock Units · Derivative | 26,570 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001140361-18-028130 · doc1.xml · derivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,570 Underlying: Common Stock · 26,570 shares Expires 2028-06-08 F1 · derivative.exercise_date: Restricted Stock Options will vest 100%, in equal quarterly installments, over a 12 month period. Read SEC document |
| June 08, 2018 Filed Jul 17, 2018 15:19 UTC Amendment | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantCommon Stock | 31,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-032709 · doc1.xml · nonDerivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,401 F1 · security: The Common Stock represents Restricted Stock Units issued to the recipient, in lieu of a portion of his Board compensation, on 6/8/18 at the closing price of $2.07. The Restricted Stock Units will vest 100%, in equal quarterly installments, over a 12 month period. F2 · shares: This amendment corrects the number of Restricted Stock Units granted. The amendment also moves the grant of the Restricted Stock Units from Table II to Table I. Read SEC document |
| May 25, 2018 Filed May 30, 2018 16:38 UTC | MELINTA THERAPEUTICS, INC. /NEW/ MLNT · Entity 154249 | PurchaseCommon Stock | 5,000 | $6.09 | $30,450.00 |
DisclosureSEC source: 0000899243-18-014450 · doc4.xml · nonDerivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Read SEC document |
| April 24, 2018 Filed Apr 26, 2018 13:36 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 22,696 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001570562-18-000021 · wf-form4_152476415212778.xml · derivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,696 Underlying: Common Stock · 22,696 shares Expires 2028-04-24 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of two years, with 1/2 of the shares subject to the option vesting annually on the anniversary of February 12, 2018. Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 17:00 UTC | Ocugen, Inc. HSGX · Entity 5550 | PurchaseCommon Stock | 3,000 | $1.81 | $5,439.00 |
DisclosureSEC source: 0000899243-17-020616 · doc4.xml · nonDerivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 F1 · price: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 17:00 UTC | Ocugen, Inc. HSGX · Entity 5550 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000899243-17-016391 · doc4.xml · derivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 13, 2017. Read SEC document |
| May 16, 2017 Filed May 17, 2017 17:00 UTC | Ocugen, Inc. HSGX · Entity 5550 | PurchaseCommon Stock | 3,000 | $1.68 | $5,040.00 |
DisclosureSEC source: 0000899243-17-013537 · doc4.xml · nonDerivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 F1 · price: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 07:46 UTC | MELINTA THERAPEUTICS, INC. /NEW/ CEMP · Entity 154249 | PurchaseCommon Stock | 5,000 | $2.94 | $14,720.00 |
DisclosureSEC source: 0001209191-17-000499 · doc4.xml · nonDerivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:56 UTC | MELINTA THERAPEUTICS, INC. /NEW/ CEMP · Entity 154249 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001209191-17-002491 · doc4.xml · derivative · entry 7 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-01-02 F6 · derivative.exercise_date: The option vests on the following schedule: 1/12th of the shares vest monthly at the end of each month over 12 months, beginning after 01/01/2017. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 17:05 UTC | Ocugen, Inc. HSGX · Entity 5550 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0000899243-16-035947 · doc4.xml · derivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-12-16 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 22, 2016. Read SEC document |
| December 15, 2016 Filed Dec 15, 2016 17:15 UTC | Ocugen, Inc. HSGX · Entity 5550 | PurchaseCommon Stock | 3,000 | $1.65 | $4,950.00 |
DisclosureSEC source: 0000899243-16-035625 · doc4.xml · nonDerivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Read SEC document |
| December 09, 2016 Filed Dec 15, 2016 17:00 UTC | Ocugen, Inc. HSGX · Entity 5550 | PurchaseCommon Stock | 5,000 | $1.92 | $9,600.00 |
DisclosureSEC source: 0000899243-16-035615 · doc4.xml · nonDerivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 10:21 UTC | EndoChoice Holdings, Inc. GI · Entity 180876 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 53,825 | Not disclosed Strike: $16.01 | Not disclosed |
DisclosureSEC source: 0001623919-16-000098 · wf-form4_147991449693774.xml · derivative · entry 4 GILL DAVID N · CIK 0001106519 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock, par value $0.001 per share · 53,825 shares Expires 2025-08-14 F4 · security: Issuer's outstanding stock options, if not yet vested, became fully vested pursuant to the terms and conditions of the Merger. F5 · security: This option was cancelled pursuant to the Merger. Since the exercise price of this option exceeded the merger consideration of $8.00 per common shares, no value was received by the reporting person. F5 · price: This option was cancelled pursuant to the Merger. Since the exercise price of this option exceeded the merger consideration of $8.00 per common shares, no value was received by the reporting person. F4 · derivative.exercise_date: Issuer's outstanding stock options, if not yet vested, became fully vested pursuant to the terms and conditions of the Merger. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 10:21 UTC | EndoChoice Holdings, Inc. GI · Entity 180876 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 32,230 | Not disclosed Strike: $5.31 | Not disclosed |
DisclosureSEC source: 0001623919-16-000098 · wf-form4_147991449693774.xml · derivative · entry 3 GILL DAVID N · CIK 0001106519 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock, par value $0.001 per share · 32,230 shares Expires 2026-03-29 F3 · security: This option was cancelled pursuant to the Merger in exchange for a cash payment representing the difference between the exercise price of the option and the merger consideration of $8.00 per share. F3 · price: This option was cancelled pursuant to the Merger in exchange for a cash payment representing the difference between the exercise price of the option and the merger consideration of $8.00 per share. F4 · derivative.exercise_date: Issuer's outstanding stock options, if not yet vested, became fully vested pursuant to the terms and conditions of the Merger. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 10:21 UTC | EndoChoice Holdings, Inc. GI · Entity 180876 | Disposition to issuerCommon stock, par value $0.001 per share | 38,585 | $8.00 | $308,680.00 |
DisclosureSEC source: 0001623919-16-000098 · wf-form4_147991449693774.xml · nonDerivative · entry 2 GILL DAVID N · CIK 0001106519 · President and CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By David N. Gill & Diane P. Gill Joint Living Trust Disclosed balance after: 0 F1 · shares: From April 1, 2016 through and including November 14, 2016, the reporting person transferred directly held shares to his indirectly held joint living trust, which resulted in a decrease in direct shares held and an increase in indirect shares held. F2 · acquired: Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 10:21 UTC | EndoChoice Holdings, Inc. GI · Entity 180876 | Disposition to issuerCommon stock, par value $0.001 per share | 125,445 | $8.00 | $1,003,560.00 |
DisclosureSEC source: 0001623919-16-000098 · wf-form4_147991449693774.xml · nonDerivative · entry 1 GILL DAVID N · CIK 0001106519 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: From April 1, 2016 through and including November 14, 2016, the reporting person transferred directly held shares to his indirectly held joint living trust, which resulted in a decrease in direct shares held and an increase in indirect shares held. F2 · acquired: Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.